Case of pembrolizumab-induced dermatomyositis with anti-transcription intermediary factor 1-γ antibody

J Dermatol. 2022 Sep;49(9):e311-e312. doi: 10.1111/1346-8138.16426. Epub 2022 May 11.

Authors

Affiliations

¹ Department of Dermatology, Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan.
² Department of Urology, Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan.

PMID: 35546739
DOI: 10.1111/1346-8138.16426

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged, 80 and over
Antibodies, Monoclonal, Humanized / adverse effects
Autoantibodies
Dermatomyositis* / chemically induced
Dermatomyositis* / diagnosis
Dermatomyositis* / drug therapy
Female
Humans
Mediation Analysis

Substances

Antibodies, Monoclonal, Humanized
Autoantibodies
pembrolizumab